Real-world studies with 7-year or 10-year follow-up with correlation of mean number of total injections given, baseline visual acuity, final visual acuity and change in visual acuity
| Baseline VA (ETDRS letters, mean) | Mean change in VA (ETDRS letters, mean) | Mean total number of injections | Final VA (ETDRS letters, mean) | |
| Studies with 7-year follow-up | ||||
| This study, 7-year follow-up (n=194) | 62 | –1.8 | 38.9 | 60.2 |
| Rofagha et al13 SEVEN-UP (n=65) | 54.3 | –8.6 | 34.6 | 45.7 |
| Gillies et al14 (n=131) | 61 | –2.7 | 36 | 58.3 |
| Berg et al15 (n=40) | 62.6 | –0.9 | 45 | 61.7 |
| Westborg et al16 (n=322) | 54.3 | –1 | 21.4 | 53.3 |
| Brynskov et al17 (n=288) | 63 | –3.3 | 30.9 | 59.7 |
| Pearson correlate | 0.18† | 0.43* | ||
| P value (two-tail sig.) | 0.97 | 0.40 | ||
| Studies with 10-year follow-up | ||||
| This study, 10-year follow-up (n=43) | 61 | –4.3 | 53.8 | 56.7 |
| Gillies et al18 2019 ANZ (n=132) | 60.7 | –0.9 | 53 | 59.8 |
| Gillies et al 2019 SWI (n=37) | 61.6 | –14.9 | 42 | 46.7 |
| Chandra et al19 (n=149) | 59.5 | –2.1 | 52.2 | 57.4 |
| Brynskov et al17 (n=74) | 61.5 | –5 | 42.9 | 56.5 |
| Pearson correlate | 0.76* | 0.72† | ||
| P value (two-tail sig.) | 0.14 | 0.17 |
*Pearson correlation of mean change in VA and mean total number of injections.
†Pearson correlation of final VA and mean total number of injections.
ANZ, New Zealand; ETDRS, Early Treatment Diabetic Retinopathy Study; SWI, Switzerland; VA, visual acuity.